On February 11, 2017, Dr. Lapuerta spoke to NorCal CarciNET Community about the challenges of bringing new drugs to market. Some interesting information to think about while you look at the slides. For Lexicon to bring a new drug to market for Carcinoid Syndrome (CS) they have worked nearly 20 years with the last 10 being in a clinical phase. They have at various times employed up to 750 people working on different aspects of the two different drugs they have worked on (one for CS the other for Diabetes). They will have spent nearly $2billion prior to the approval of either of the two drugs (a little less than half on the drug for CS.)
PDF not showing up.. You can download it here.
Sixth Annual Bay Area Neuroendocrine Patient Education Conference
A free educational conference for patients and caregivers.
Hosted by the Stanford Cancer Center and the NET Research Foundation,
in cooperation with UCSF Helen Diller Family Comprehensive Cancer Center and the NorCal CarciNET Community
We are pleased to bring together our extensive community of patients, loved ones, medical professionals, and supporters for the 2017 Bay Area Neuroendocrine Tumor Patient Education Conference.
Please join us to learn more about the latest developments in research and clinical care for patients with neuroendocrine cancers.
The conference will be held on Saturday, February 4th. Check in starts at 9:00 am
Frances C. Arrillaga Alumni Center 326 Galvez Street Stanford, CA 94305-6105
On Oct 3rd 2015, Dr. Tom Hope from UCSF spoke to 60 members of the NorCal CarciNET Support Community on imaging. The slides he presented are available by clicking here. While the nearly two hour session was not recorded, we are pleased to share an earlier presentation that Dr. Hope gave at the 3rd Theranostics World Congress in March of this year.